Immunotherapies break into cold colorectal cancers at ASCO 2024

Several immuno-oncology mechanisms on display at ASCO 2024 help the field inch closer to solving one of cancer immunotherapy’s biggest problems: achieving efficacy in cold solid tumors.

These mechanisms include bispecific antibodies that engage multiple T cell activation signals, immunocytokine therapies that couple checkpoint inhibition with immune stimulating cytokines, and combinations of innate immune activators. ...